ImmuPharma (LON:IMM) Stock Price Down 9.2% - Here's What Happened

Key Points

• ImmuPharma's stock price fell by 9.2%, trading between GBX 14.10 and GBX 15.99 during mid-day trading on Tuesday.
• The company's market capitalization is £74.46 million, with a PE ratio of -1,674.16 and a beta of 1.53.
• ImmuPharma reported negative earnings per share (EPS) of GBX (0.38) for the last quarter, and analysts project a yearly EPS of -339.0000022.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded down 9.2% during mid-day trading on Tuesday . The company traded as low as GBX 14.10 ($0.19) and last traded at GBX 15.99 ($0.22). 30,565,963 shares were traded during trading, an increase of 264% from the average session volume of 8,394,776 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Trading Down 15.3%

The business's 50 day simple moving average is GBX 3.43 and its two-hundred day simple moving average is GBX 3.01. The firm has a market capitalization of £74.46 million, a PE ratio of -1,674.16 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.